Brivaracetam Intermediate Synthesis for High-Purity Scale-Up
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing synthetic routes for Brivaracetam face harsh reaction conditions, low yield, high cost, and unsuitability for industrial-scale production due to the need for toxic reagents and cumbersome purification steps.
Innovation Solution
A novel synthesis method involving intermediate compounds A and B, using copper-containing catalysts and specific organic solvents, eliminates the need for toxic reagents and cumbersome purification, enabling high-yield production suitable for industrial scale.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional synthetic routes are used to prepare Brivaracetam, then the reaction can proceed with conventional reagents, but the reaction conditions become harsh and the yield decreases
Solution Approach 1:
The patent changes the reaction parameters by using copper-containing catalysts (such as copper iodide, copper bromide, or copper chloride) combined with specific ligands (like N,N-dimethylglycine, N-methylglycine, or sarcosine) to enable the reaction to proceed under milder conditions with higher yield. This transforms the harsh traditional conditions into optimized parameters that improve productivity.
Solution Approach 2:
The patent introduces copper-containing catalysts as intermediaries to facilitate the reaction between the starting material and reagents. These catalysts act as mediators that lower the activation energy and enable the reaction to proceed under milder conditions, thereby improving yield without requiring harsh temperature or pressure conditions.
2Object-affected harmful factors
If traditional synthetic routes are used to prepare Brivaracetam, then the reaction can proceed with conventional reagents, but toxic reagents must be used
Solution Approach 1:
The patent replaces toxic reagents (such as ethyl chloroformate and trimethylsilyl iodide) with less toxic alternatives (copper-containing catalysts combined with amino acid ligands). This conversion eliminates harmful factors while maintaining or improving reaction efficiency and yield, making the process safer for industrial production.
Solution Approach 2:
The patent uses copper-containing catalysts that can be easily removed and disposed of after the reaction, replacing the need for complex purification steps required by toxic reagents. This approach reduces both toxicity and production costs while maintaining high yield.
3Productivity
If traditional synthetic routes are used to prepare Brivaracetam, then the reaction can proceed with conventional methods, but the number of reaction steps increases
Solution Approach 1:
The patent merges multiple reaction steps into a more streamlined sequence by using copper-catalyzed reactions that can proceed directly from the starting material to the intermediate compound. This consolidation reduces the total number of steps and synthesis time while improving overall productivity.
Solution Approach 2:
The patent performs the copper-catalyzed reaction under optimized conditions that prepare the intermediate compound in advance with high purity, eliminating the need for intermediate purification steps and reducing the overall number of operations required in the synthesis pathway.
4Ease of manufacture
If traditional synthetic routes are used to prepare Brivaracetam, then the reaction can proceed with conventional reagents, but the purification process becomes cumbersome
Solution Approach 1:
The patent extracts or removes the need for complex purification steps (such as silica gel column chromatography and chiral preparative column separation) by using copper-catalyzed reactions that produce high-purity intermediates directly. This simplification makes the manufacturing process easier and reduces production costs.
Solution Approach 2:
The reaction system itself produces the intermediate compound with sufficient purity through the copper-catalyzed process, eliminating the need for external purification interventions. The reaction conditions and catalyst system work together to self-purify the product, reducing both operational complexity and cost.
5Adaptability or versatility
If traditional synthetic routes are used to prepare Brivaracetam, then the reaction can proceed with conventional methods, but the process is unsuitable for industrial-scale production
Solution Approach 1:
The patent optimizes reaction parameters (catalyst type, ligand selection, temperature, and solvent conditions) to produce intermediates with purity levels that meet industrial requirements without needing post-purification steps. This makes the process adaptable to large-scale production while maintaining high purity standards.
Solution Approach 2:
The patent converts the challenge of meeting strict purity requirements into an advantage by using copper-catalyzed reactions that inherently produce high-purity products. This eliminates the need for complex purification infrastructure and makes the process more suitable for industrial-scale production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves high-quality Brivaracetam with >99.5% optical purity, reducing production costs and making it suitable for industrial production without requiring silica gel or chiral chromatography.
Implementation Method 1
the reaction is carried out under a copper-containing catalyst
Implementation Method 2
the reaction medium in the above reaction is an organic solvent
Data Source
AI summary
The present disclosure provides intermediates used for preparing Brivaracetam, a preparation method and a use thereof, including an intermediate compound A and an intermediate compound B and a preparation method thereof, as well as a synthetic route for using the intermediate compound B to prepare Brivaracetam. The present technical solution can obtain high-quality and high-optical purity Brivaracetam and intermediates thereof, the proportion of Brivaracetam among the four optical isomers being greater than 99.5%. In addition, neither silica gel column for separation and purification nor expensive chiral high performance liquid chromatography for resolution is required, thereby avoiding cumbersome separation and purification steps, also avoiding waste of raw materials, reducing the production cost and making it more suitable for industrial production.